A global women’s health market valued at $360 billion [1] is attracting new investment after being overlooked by the medical industry for decades.
This shift represents a correction of a long-term systemic failure in healthcare. For roughly 20 years, pharmaceutical companies and biotech firms ignored the specific needs of mid-life women, leading to a gap in treatment and productivity for about 50 percent of the global population [2].
Menopause and other mid-life health issues have historically been under-prioritized by medical professionals and employers. This neglect occurred despite the significant impact these conditions have on a woman's quality of life, and her ability to remain in the workforce. The lack of targeted research left a massive void in a sector that affects billions of people globally.
Now, a new ecosystem of stakeholders is filling that gap. Startups such as Midi Health and Stripes are developing specialized services to address these unmet needs. These ventures are increasingly supported by venture capital firms, including Amboy Street Ventures, which are recognizing the commercial potential of the underserved sector.
Celebrities are also using their platforms to bring visibility to the issue. Naomi Watts has become one of the high-profile figures engaging with the movement to destigmatize menopause and advocate for better medical standards. Their involvement helps transition these health concerns from private struggles to public health priorities.
This surge in activity marks a transition from a period of medical stagnation to one of rapid innovation. As biotech and pharma begin to pivot toward women's health, the focus is shifting toward personalized medicine, and specialized care for the aging female body.
“A $360 billion global women’s health market has been ignored for roughly two decades.”
The emergence of a dedicated women's health economy suggests that market forces are finally aligning with a long-ignored public health need. By treating menopause and mid-life health as a viable investment sector rather than a niche concern, the industry may accelerate the development of treatments that reduce workplace attrition and improve long-term health outcomes for women globally.
